CRISPR Therapeutics (CRSP) has completed a private offering of US$550 million in convertible senior notes due 2031, upsized from an initially announced US$350 million, drawing investor attention to its funding mix.

The financing news has arrived during a weak patch for the shares, with a 1-day share price return showing a 5.44% decline and a 7-day share price return showing a 16.78% decline. This comes even as the 1-year total shareholder return of 14.81% points to underlying optimism that has faded in recent months.

If this fundraising has you looking across biotech, it could be a good moment to scan other gene editing and AI linked names using our screener of 34 healthcare AI stocks.

So with CRISPR Therapeutics trading around US$49.93 and screens flagging a roughly 74% intrinsic discount, is the recent sell off setting up a mispriced gene editing player, or is the market already factoring in much of its potential future growth?

Preferred Price-to-Book Multiple of 2.5x: Is it justified?

CRISPR Therapeutics closed at $49.93, and on a P/B of 2.5x it screens as good value against both its biotech peers and the broader US Biotechs industry.

The P/B ratio compares the company’s market value to its book value, which is essentially the net assets on the balance sheet. For early stage or unprofitable biotech names where earnings are not yet a guide, investors often look at P/B to see how the market is pricing cash, intellectual property and the development pipeline.

Here, CRISPR Therapeutics’ 2.5x P/B sits below the US Biotechs industry average of 2.7x and far below the cited peer group average of 16.5x. That gap suggests the market is assigning a lower premium to CRISPR Therapeutics’ assets and pipeline than to many comparables, even though revenue is forecast to grow 58.5% per year while the company is expected to remain unprofitable over the next three years.

Result: Price-to-book of 2.5x (UNDERVALUED)

However, you still need to weigh clinical and regulatory setbacks around programs like CASGEVY, along with ongoing net losses of $581.599 million on revenue of $3.51 million.

Another View on Value: Our DCF Result

The P/B of 2.5x presents CRISPR Therapeutics as inexpensive, but our DCF model indicates something stronger. The share price of $49.93 sits 73.9% below an estimated future cash flow value of $190.99. This raises the question of whether there is a margin of safety or whether the cash flow outlook is too optimistic.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out CRISPR Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 50 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Does this mix of caution and optimism match how you see CRISPR Therapeutics right now? Take a closer look at the full picture with 2 key rewards and 2 important warning signs.

Looking for more investment ideas?

If CRISPR has your attention, do not stop here. Put a few more high quality ideas on your radar so you are not leaving opportunities on the table.

• Target stronger value potential by scanning our list of 50 high quality undervalued stocks that pair appealing prices with solid fundamentals.
• Prioritise resilience by checking out 67 resilient stocks with low risk scores, focusing on companies with steadier risk profiles that may suit a more cautious approach.
• Get ahead of the crowd by reviewing our screener containing 23 high quality undiscovered gems, where lesser known names with robust data might be waiting for attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.